Heparin activation of protein Z-dependent protease inhibitor (ZPI) allosterically blocks protein Z activation through an extended heparin-binding site

Xin Huang1,*, Richard Swanson‡, and Steven T. Olson‡

From the 1Department of Pharmacology and Regenerative Medicine and 2Department of Periodontics, University of Illinois Chicago, Chicago, Illinois, USA

Edited by George DeMartino

Heparin binding protein protease inhibitors of the serpin family play an important role in regulating the activity of proteases of the blood clotting cascade. As a cofactor, heparin accelerates the inhibition of clotting proteases by the serpins, antithrombin (AT, serpin C1), heparin cofactor II (HCII, serpin D1), protease nexin 1 (PN-1, serpin E2), and protein C inhibitor (PCI, serpin A5) up to several 1000-fold (1). Because of this potent stimulating effect, heparin has long been used as an antithrombotic medication in clinical practice. The mechanism of this potent stimulating effect, heparin has long been used as an antithrombotic medication in clinical practice. The heparin-binding site of these serpins has been well characterized. Basic residues on Helix D of AT, HCII, and PN-1 mediate heparin interactions with these serpins (2–4), whereas for PCI, the heparin-binding site is mainly composed of basic residues around helix H (5, 6).

Protein Z (PZ)-dependent protease inhibitor (ZPI) is a plasma anticoagulant protein of the serpin superfamily, which is activated by its cofactor, PZ, to rapidly inhibit activated factor X (FXa) on a procoagulant membrane surface. ZPI is also activated by heparin to inhibit free FXa at a physiologically significant rate. Here, we show that heparin binding to ZPI antagonizes PZ binding to and activation of ZPI. Virtual docking of heparin to ZPI showed that a heparin-binding site near helix H close to the PZ-binding site as well as a previously mapped site in helix C was both favored. Alanine scanning mutagenesis of the helix H and helix C sites demonstrated that both sites were critical for heparin activation. The binding of heparin chains 72 to 5-saccharides in length to ZPI was similarly effective in antagonizing PZ binding and in inducing tryptophan fluorescence changes in ZPI. Heparin binding to variant ZPIs with either the helix C sites or the helix H sites mutated showed that heparin interaction with the higher affinity helix C site most distant from the PZ-binding site was sufficient to induce these tryptophan fluorescence changes. Together, these findings suggest that heparin binding to a site on ZPI extending from helix C to helix H promotes ZPI inhibition of FXa and allosterically antagonizes PZ binding to ZPI through long-range conformational changes. Heparin antagonism of PZ binding to ZPI may serve to spare limiting PZ and allow PZ and heparin cofactors to target FXa at different sites of action.

Heparin-binding protein protease inhibitors of the serpin family play an important role in regulating the activity of proteases of the blood clotting cascade. As a cofactor, heparin accelerates the inhibition of clotting proteases by the serpins, antithrombin (AT, serpin C1), heparin cofactor II (HCII, serpin D1), protease nexin 1 (PN-1, serpin E2), and protein C inhibitor (PCI, serpin A5) up to several 1000-fold (1). Because of this potent stimulating effect, heparin has long been used as an antithrombotic medication in clinical practice. The heparin-binding site of these serpins has been well characterized. Basic residues on Helix D of AT, HCII, and PN-1 mediate heparin interactions with these serpins (2–4), whereas for PCI, the heparin-binding site is mainly composed of basic residues around helix H (5, 6).

Protein Z (PZ)-dependent protease inhibitor (ZPI) is a serpin that circulates in plasma as a tight complex with its cofactor, PZ, at a concentration of ~50 nM (7, 8). ZPI plays an important anticoagulant role by rapidly inhibiting activated factor X (FXa) in the presence of PZ, procoagulant lipids, and calcium. ZPI also directly inhibits activated factor XI (9). Heparin is also a physiologically relevant cofactor for ZPI regulation of its protease targets, enhancing both ZPI–FXa and ZPI–activated factor XI reaction rates to the physiologically relevant range (10–11).  

The heparin-binding site of ZPI has been previously mapped to basic residues of helices C and D (11), a site far removed from the PZ-binding site centered on helix G (12, 13). We were therefore surprised to find in a recent study that heparin appeared to antagonize the ZPI–PZ interaction by inducing the ZPI–PZ complex to dissociate (14). This suggested that heparin might actually bind to an additional site closer to the PZ-binding site so as to interfere with PZ binding. In the present study, we have used web-based computer–ligand docking tools together with mutagenesis to demonstrate a novel extended heparin-binding site on ZPI that extends from the previously mapped site in helix C to helix H and which is critical for heparin activation of ZPI anticoagulant function. We in addition exploit intrinsic and extrinsic fluorophore reporters on ZPI to provide evidence that heparin binding to ZPI interferes with PZ binding not by proximity effects but through allosterically induced conformational changes in ZPI, which weaken PZ binding. The implications for how heparin and PZ cofactors regulate ZPI anticoagulant function under physiological conditions are discussed.

Results

Heparin is an antagonist of the ZPI–PZ interaction

In a recent study, we analyzed ZPI–PZ complex formation in the absence and presence of a 50-saccharide heparin (H50) representing the average chain length of naturally occurring heparin by gel-filtration chromatography and surprisingly
found that heparin had caused the ZPI–PZ complex to dissociate (14). To further substantiate the antagonistic action of heparin on the ZPI–PZ interaction, we applied the proteins alone and in complex to a small column of heparin-Sepharose resin followed by eluting the unbound proteins with physiology buffer. As expected, applying ZPI alone resulted in the detection of ZPI on the heparin-Sepharose resin and not in the flowthrough (sample 1, Fig. 1), indicating its complete binding to the immobilized heparin. In contrast, applying PZ alone resulted in the detection of PZ only in the flowthrough and not on the resin (sample 3), indicating that PZ does not bind heparin-Sepharose. When ZPI–PZ complex was applied to the heparin-Sepharose column, only ZPI was detected on the resin, whereas PZ was found only in the flowthrough along with a trace of ZPI (sample 2), indicating that even when complexed with ZPI, PZ is unable to bind heparin-Sepharose through its high-affinity interaction with ZPI.

We further analyzed ZPI, PZ, and heparin interactions using a single cysteine ZPI mutant (Lys 239 Cys) labeled with the fluorophore, N,N’-dimethyl-N-(acetyl)-N’-(7-nitrobenz-3-oxa-1,3-diazol-4-yl) ethylenediamine (NBD), a probe we developed previously (15). Residue 239 is located on the periphery of the ZPI–PZ binding interface, and an NBD label at this position is highly sensitive to PZ binding as reflected by the ~300% enhancement in NBD fluorescence when saturating PZ is added to the labeled ZPI (Fig. 2A). By contrast, addition of the H50 to the NBD-labeled ZPI at levels sufficient to saturate the protein caused minimal changes in NBD fluorescence, implying that NBD at position 239 does not sense heparin binding and is thus more distant from the heparin-binding site. When the equivalent saturating level of H50 was added to NBD-labeled ZPI complexed with PZ, however, a nearly complete quenching of the enhanced NBD fluorescence of the complexed ZPI was observed, suggesting that heparin binding to the NBD–ZPI/PZ complex had caused the dissociation of PZ (Fig. 2A). Titrations of the NBD–ZPI–PZ complex with naturally occurring 26- to 72-saccharide heparins (H72) as well as oligosaccharide heparin chains ranging from 18 to four saccharides showed that all except the 4-saccharide heparin were able to dose-dependently and saturably quench the fluorescence signal of the NBD–ZPI/PZ complex in accordance with a competitive binding model (Fig. 2B). Full-length and oligosaccharide heparin chains as small as a pentasaccharide were thus all effective at competitively displacing PZ from its complex with ZPI. Progressively higher heparin concentrations were necessary to achieve similar levels of quenching as the heparin chain length decreased, indicating that heparin binding to ZPI displaced PZ from the ZPI–PZ complex with an affinity dependent on heparin chain length, in keeping with past findings (10). Fitting these titrations with the competitive binding equation confirmed that \( K_D \) for heparin binding to NBD–ZPI increased from ~0.1 \( \mu \)M for the H72 to ~30 \( \mu \)M for the pentasaccharide heparin (H5) (Table 1). These values compare well with values kinetically determined from the concentration dependence of the heparin-accelerating effect on heparin concentration in our previous study (10).

Competition between heparin and PZ for binding to ZPI was further demonstrated by titrating NBD-labeled ZPI with PZ in the absence and presence of fixed levels of H5 or full-length heparin chains (Fig. 2, C and D). Fitting of the titration data by the binding equation showed that the apparent PZ-binding affinity was progressively decreased as the fixed heparin concentration was increased (Table 2). \( K_D \)s inferred for ZPI–heparin interactions from the observed decreases in PZ-binding affinity assuming a competitive binding model compared reasonably well with those determined by direct heparin-binding fluorescence titrations of unlabeled ZPI under the higher ionic strength conditions of these experiments.

**ZPI protein fluorescence is perturbed by heparin binding**

Heparin binding to ZPI was found to be accompanied by changes in ZPI intrinsic protein fluorescence. Addition of near saturating levels of either the H5 or the full-length H72 to ZPI resulted in a similar 15 to 20% quenching of the protein fluorescence emission spectrum of the protein (Fig. 3, A and B). Titrations of ZPI with the H5s or the H72s showed that the

![Figure 1. Immunoblotting analysis of ZPI, PZ, and ZPI–PZ complex interactions with heparin-Sepharose.](Image)
fluorescence quenching was saturable and could be fit by the quadratic binding equation to yield a maximal quenching of $-15 \pm 1\%$ and $K_D$ of 123 $\pm$ 23 $\mu$M for H5 binding and quenching of $-19 \pm 1\%$ and $K_D$ of 1.1 $\pm$ 0.1 $\mu$M for H72 binding (Fig. 3, C and D).

Table 1

| Heparin chain length (saccharides) | ZPI–heparin $K_{D,H}$ ($\mu$M) |
|-----------------------------------|---------------------------------|
| 4                                 | Not measurable                  |
| 5                                 | 32.4 $\pm$ 1.9                  |
| 10                                | 15.9 $\pm$ 1.6                  |
| 14                                | 8.1 $\pm$ 0.6                   |
| 18                                | 2.3 $\pm$ 0.3                   |
| 26                                | 1.2 $\pm$ 0.06                  |
| 50                                | 0.5 $\pm$ 0.01                  |
| 72                                | 0.07 $\pm$ 0.006                |

Dissociation constants ($K_{D,H}$) for ZPI–heparin interaction with heparins of varying chain length were determined by fitting competitive binding titrations of NBD-ZPI–PZ complex with heparin in Figure 2B by the equation in the “Experimental procedures” section.

ZPI–heparin docking analysis predicts two favored heparin-binding sites

The aforementioned findings clearly demonstrated that heparin binding to ZPI antagonizes PZ binding. This was surprising given that a previous mapping of the ZPI heparin-binding sites had been determined by a different approach.

Table 2

| Heparin | (Heparin)$_H$ ($\mu$M) | ZPI–PZ $K_{D,PZapp}$ (nM) | ZPI–heparin $K_{D,H}$ ($\mu$M) |
|---------|------------------------|-----------------------------|---------------------------------|
| None    |                        | 9.0 $\pm$ 1.2               | 53                             |
| H5      | 211                    | 44.8 $\pm$ 3.7              | 44                             |
| H5      | 423                    | 95.6 $\pm$ 12.2             | 4.4                            |
| H72     | 2                      | 52.3 $\pm$ 4.9              | 0.42                           |
| H72     | 4                      | 83.6 $\pm$ 10.1             | 0.48                           |
| H26     | 472                    | 218.0 $\pm$ 15.0            | 3.1                            |
| H50     | 55                    | 410.0 $\pm$ 42.0            | 1.2                            |

Apparent dissociation constants for NBD-ZPI–PZ and NBD-ZPI–heparin interactions were determined by fitting competitive binding titrations of NBD-ZPI–PZ complex with heparin in the absence and presence of varying chain-length heparins. The data were analyzed by the equation for a competitive binding interaction, $K_{D,PZapp} = K_{D,ZPI} \times (1 + [H]/K_{D,H})$, given in the “Experimental procedures” section.
Binding site implicated a site distant from the PZ binding site (11). The previous observations that mutation of basic residues in this site did not completely abrogate heparin binding to ZPI or heparin acceleration of ZPI inhibition of FXa, however, suggested that an additional basic site on ZPI for heparin binding might exist close to the PZ-binding site so as to interfere with PZ binding. To assess this possibility, we employed the docking program, CLUSPRO (http://cluspro.bu.edu) (16), to predict the most likely basic regions of ZPI to bind a tetrasaccharide heparin. Inputting the native ZPI chains of the two human ZPI–PZ complex structures (Protein Data Bank [PDB] code: 3F1S (12) and 3H5C (13)) that have been reported resulted in two favored heparin-binding sites, one in the helix C site previously mapped and another in a novel site close to helix H and adjacent to the PZ-binding site (Fig. 4). Notably, the latter site is immediately adjacent to the helix H site for heparin binding to the related A clade serpin, PCI (5, 6). Surprisingly, when the docking analysis was performed with the mouse uncomplexed native ZPI structure (PDB code: 4AJT) (17), only the helix H site was predicted. Alignment of human and mouse ZPI sequences showed that the reason for this was that the helix C site is not conserved in the mouse sequence. Alignment of other ZPI vertebrate sequences confirmed a strong conservation of the helix H basic residues and lack of conservation of the helix C site (Fig. 5).

**Validation of the predicted heparin-binding site by mutagenesis**

To determine whether the predicted helix H-binding site for heparin on ZPI was involved in heparin cofactor function, we proceeded to mutate the residues in the predicted site singly and in combination and analyze how the mutations affected the ability of heparin to accelerate ZPI inhibition of FXa. Because ZPI is not a completely efficient inhibitor of FXa in the absence or the presence of heparin or PZ cofactors and can be cleaved by FXa as a substrate in a competing reaction, as reflected by stoichiometries of inhibition (SIs) greater than 1, kinetic evaluations of ZPI–FXa reactions must correct the apparent rate constant for ZPI inhibition of FXa by multiplying by the SI (18).

As a control, we first determined whether the predicted helix H site mutations affected the PZ cofactor function of ZPI. Table 3 shows that PZ produced a robust acceleration of FXa inhibition by the helix H mutant ZPIs in the presence of phospholipid and calcium relative to unaccelerated rates of
inhibition, demonstrating that the mutations minimally perturbed PZ activation of ZPI anticoagulant function. By contrast, a D293A ZPI mutation in the PZ-binding site greatly abrogated the acceleration, in keeping with our previous demonstration that D293 is a hot spot residue for PZ binding (17).

Full-length heparins accelerate the ZPI–FXa reaction through a template bridging mechanism, which is reflected by the bell-shaped dependence of the acceleration on heparin concentration. The maximum acceleration of the WT ZPI reaction by H50 occurs at about 1 μM heparin under physiologic conditions (Fig. 6). Analysis of the kinetics of H50 acceleration of mutant ZPI–FXa reactions as a function of heparin concentration showed a similar bell-shaped dependence and optimal acceleration at ~1 μM heparin. Notably, several single and combined mutations in the predicted helix H site significantly reduced the extent of heparin acceleration of the ZPI–FXa reaction, suggesting that the predicted site was indeed important for heparin cofactor function (Fig. 6).

We proceeded to compare the effects of the ZPI mutations on H50-accelerated and unaccelerated second-order inhibition rate constants for ZPI–FXa reactions at the optimal heparin concentration of 1 μM. Table 4 tabulates the measured apparent rate constants (kapp), SIs, and corrected inhibition rate constants for WT and all mutant ZPI reactions with FXa in the presence of the H50. H50 accelerated WT ZPI inhibition of FXa ~75-fold over the unaccelerated rate of inhibition (Tables 3 and 4). The accelerating effect was unaffected for the K284A mutation (close to D293) and modestly reduced to 56-fold for the K253A mutant and to 55-fold for the R263A mutant. However, more significant reductions in heparin acceleration from 75-fold to ~27-fold for K260A, ~29-fold for R305A, ~32-fold for K308A, and ~35-fold for R310A were observed. Notably, mutation of the hot spot PZ-binding residue, D293A, produced a WT-like heparin acceleration, indicating that loss of PZ-binding function did not affect heparin cofactor function. While combining the K284A and R310A mutations did not further reduce the acceleration from that of the single R310A mutation (~59-fold), the double mutation, K260A/R263A, strongly reduced the acceleration from 75-fold to ~22-fold, implying a cumulative effect of these latter two residues. Combining the K260A/R263A double mutation with K308A and R310A mutations produced a somewhat further cumulative reduction in the quadruple mutant K260A/R263A/K308A/R310A acceleration to ~17-fold. This reduction was further augmented to a 6.5-fold heparin acceleration by adding the R305A mutation to yield the quintuple mutant, K260A/R263A/K308A/R310A/K305A/R308A acceleration to ~17-fold. The addition of the nearby K253A mutation to the quintuple mutant to yield the sextuple mutant, K253A/K260A/R263A/K308A/R310A/K305A/R308A/R310A, produced no further reduction (approximately ninefold) in the heparin acceleration, suggesting that the five residues in the quintuple mutant were sufficient to produce the maximum reduction in heparin acceleration of >90%. The five residues, K260, R263, R305, K308, and R310, thus appear to constitute a cluster critical for heparin activation of ZPI to inhibit FXa, in agreement with the heparin-binding site predicted by CLUSPRO (Fig. 4).

Three of these residues (R305, R308, and R310) reside between the C terminus of helix H and the N terminus of strand 2 of sheet C, close to the helix H heparin-binding site of the related A clade serpin, PCI (5, 6). The other two residues

---

**Figure 4. Virtual docking of a heparin tetrasaccharide to human and mouse ZPIs.** The ZPI chains of two human ZPI–PZ complex crystal structures colored cyan, A and B) and the uncomplexed mouse ZPI structure (C) were virtually docked to a heparin tetrasaccharide (red stick) with the program, CLUSPRO. One human ZPI structure (PDB code: 3F1S, left) predicted binding at four favored sites with a site near helix H most favored (K260, R263, K308, R310, 40% of models) followed by a helix C site (K104, R105, K113, R337, R338, 16% of models). The other human ZPI structure (PDB code: 3H5C, left) predicted the most favorable binding at the helix C site (K104, R105, K113, K116, R332, R337, R338, 92% of models) but also predicted the helix H site (K260, R310, 40% of models) followed by a helix C site (K104, R105, K113, R337, R338, 16% of models). The uncomplexed mouse ZPI structure predicted binding solely at the helix H site (K260, R310, 5% of models). ZPI basic residues predicted to bind heparin are in blue stick. PDB, Protein Data Bank; PZ, protein Z; ZPI, protein Z-dependent protease inhibitor.
Helix C is also critical for the heparin cofactor function of ZPI

The previous study that mapped the heparin-binding site of ZPI to helix C/D employed mostly a chimeric approach in which the helix C and helix D secondary structures (including the connecting loop between helix C and D) were substituted with the homologous regions in the nonheparin-binding serpin, α1-protease inhibitor (11). To confirm the importance of this site for heparin cofactor function, we chose a less perturbing alanine scanning mutagenesis approach in which only basic residues in the implicated helix C/D site were mutated. The mutation of the six basic residues in the helix C/D site, K104A/R105A/K113A/K116A/K125A/R128A, resulted in a major reduction in the heparin acceleration from 75-fold to ~7-fold (Table 4 and Fig. 5), confirming the importance of these residues for heparin cofactor function. The relative importance of helix C and D residues was further assessed by mutating helix D and helix C plus intervening loop residues alone. Notably, mutation of helix D residues, K125A/R128A, had no significant effect on heparin acceleration (~89-fold) relative to WT, whereas mutation of the four helix C intervening loop residues, K104A/R105A/K113A/K116A, produced the same major reduction in heparin acceleration (75-fold to ~8.6-fold) as that of the combined helix C/D site mutations (Table 4). Helix D thus does not appear to contribute to the heparin-binding function of this site. Interestingly, this helix C site and the newly identified helix H site are aligned on the same face of ZPI, suggesting that the two sites may form an extended site for binding full-length heparin chains (Fig. 7).

Relative contributions of helix C and helix H sites to heparin affinity for ZPI

To evaluate the relative contributions of helix C and helix H sites to heparin-binding affinity, we analyzed the elution of the mutated ZPIs from heparin-Sepharose. Consistent with previous results, the helix C site mutations substantially reduced heparin affinity, whereas surprisingly, mutating the newly identified helix H site had a more modest effect in reducing
Table 3

Second-order association rate constants and inhibition stoichiometries for unaccelerated and PZ-accelerated reactions of WT and mutant ZPIs with FXa

| ZPI mutant                  | Unaccelerated reactions |                         |                         |                         |                         |                         |                          |                          |
|-----------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                             | $k_{a,app}$ (M$^{-1}$ s$^{-1}$) | SI | $k_{a,app} \times$ SI (M$^{-1}$ s$^{-1}$) | $k_{a,app}$ (M$^{-1}$ s$^{-1}$) | SI | $k_{a,app} \times$ SI (M$^{-1}$ s$^{-1}$) | PZ enhancement$^a$ |                         |
| WT                          | 5.6 ± 0.3 × 10$^3$      | 2.8 ± 0.4               | 1.6 ± 0.3 × 10$^4$      | (1)                     | 10.9 ± 0.1 × 10$^6$    | 4.0 ± 0.3               | 4.4 ± 0.3 × 10$^7$      | (1.0)                   | 2750                    |
| D293A                       | 4.1 ± 0.2 × 10$^3$      | 2.6 ± 0.1               | 1.1 ± 0.1 × 10$^4$      | (0.69)                  | -                        | -                      | -                      | -                        |
| Helix H site mutations      |                         |                         |                         |                         |                         |                         |                          |                          |
| K253A                       | 4.1 ± 0.4 × 10$^3$      | 2.1 ± 0.1               | 8.5 ± 1.2 × 10$^3$      | (0.53)                  | 3.0 ± 0.2 × 10$^6$      | 2.4 ± 0.1               | 7.2 ± 0.1 × 10$^6$      | (0.16)                  | 847                     |
| K260A                       | 4.8 ± 0.3 × 10$^3$      | 2.2 ± 0.2               | 1.0 ± 0.2 × 10$^4$      | (0.62)                  | 8.9 ± 0.2 × 10$^6$      | 3.1 ± 0.1               | 2.6 ± 0.2 × 10$^7$      | (0.59)                  | 2600                    |
| R263A                       | 2.4 ± 0.1 × 10$^3$      | 2.7 ± 0.5               | 6.4 ± 1.3 × 10$^3$      | (0.40)                  | 6.9 ± 0.5 × 10$^6$      | 3.1 ± 0.1               | 2.1 ± 0.2 × 10$^7$      | (0.48)                  | 3359                    |
| K284A                       | 5.0 ± 0.3 × 10$^3$      | 2.3 ± 0.2               | 1.2 ± 0.2 × 10$^4$      | (0.75)                  | 6.2 ± 0.1 × 10$^6$      | 3.3 ± 0.1               | 2.0 ± 0.1 × 10$^6$      | (0.45)                  | 1733                    |
| R305A                       | 7.3 ± 0.4 × 10$^3$      | 2.4 ± 0.2               | 1.8 ± 0.2 × 10$^4$      | (1.1)                   | 9.8 ± 1.0 × 10$^6$      | 3.3 ± 0.1               | 3.2 ± 0.4 × 10$^7$      | (0.73)                  | 1778                    |
| K308A                       | 5.8 ± 0.1 × 10$^3$      | 2.9 ± 0.2               | 1.7 ± 0.1 × 10$^4$      | (1.1)                   | 9.5 ± 0.1 × 10$^6$      | 2.7 ± 0.1               | 2.6 ± 0.1 × 10$^7$      | (0.59)                  | 1524                    |
| R310A                       | 3.8 ± 0.3 × 10$^3$      | 2.7 ± 0.2               | 1.0 ± 0.2 × 10$^4$      | (0.62)                  | 9.4 ± 1.4 × 10$^6$      | 2.9 ± 0.2               | 2.7 ± 0.6 × 10$^7$      | (0.61)                  | 2700                    |
| K260A/R263A                 | 5.4 ± 0.3 × 10$^3$      | 2.4 ± 0.5               | 1.3 ± 0.4 × 10$^4$      | (0.81)                  | 5.6 ± 0.2 × 10$^6$      | 2.6 ± 0.3               | 1.5 ± 0.2 × 10$^7$      | (0.34)                  | 1153                    |
| K284A/R310A                 | 3.3 ± 0.3 × 10$^3$      | 1.9 ± 0.2               | 6.3 ± 1.3 × 10$^3$      | (0.39)                  | 6.4 ± 0.4 × 10$^6$      | 3.3 ± 0.1               | 2.1 ± 0.2 × 10$^7$      | (0.48)                  | 3317                    |
| K260A/R263A/K308A/R310A     | 1.1 ± 0.2 × 10$^3$      | 4.0 ± 0.8               | 4.5 ± 1.8 × 10$^3$      | (0.28)                  | 4.1 ± 0.3 × 10$^6$      | 6.6 ± 0.4               | 2.7 ± 0.4 × 10$^7$      | (0.61)                  | 6000                    |
| K260A/R263A/R305A/K308A/R310A| 2.6 ± 0.1 × 10$^3$      | 2.9 ± 0.3               | 7.5 ± 0.9 × 10$^3$      | (0.47)                  | 3.9 ± 0.1 × 10$^6$      | 4.5 ± 0.2               | 1.8 ± 0.1 × 10$^7$      | (0.41)                  | 2400                    |
| K253A/K260A/R263A/R305A/K308A/R310A | 9.2 ± 0.6 × 10$^2$ | 3.2 ± 0.1               | 2.9 ± 0.2 × 10$^3$      | (0.18)                  | 3.4 ± 0.1 × 10$^6$      | 7.4 ± 0.3               | 2.5 ± 0.2 × 10$^7$      | (0.57)                  | 8620                    |
| Helix C site mutations      |                         |                         |                         |                         |                         |                         |                          |                          |
| K125A/R128A                 | 3.7 ± 0.1 × 10$^3$      | 1.7 ± 0.1               | 6.3 ± 0.3 × 10$^3$      | (0.39)                  | 5.2 ± 0.2 × 10$^6$      | 5.6 ± 0.1               | 2.9 ± 0.2 × 10$^7$      | (0.66)                  | 4603                    |
| K104A/R105A/K113A/K116A     | 5.9 ± 0.1 × 10$^3$      | 2.4 ± 0.2               | 1.4 ± 0.2 × 10$^4$      | (0.88)                  | 10.1 ± 1.9 × 10$^6$     | 2.3 ± 0.1               | 2.3 ± 0.5 × 10$^7$      | (0.52)                  | 1642                    |
| K104A/R105A/K113A/K116A/K125A/R128A | 2.8 ± 0.1 × 10$^3$ | 3.4 ± 0.4               | 9.4 ± 1.6 × 10$^3$      | (0.59)                  | 1.1 ± 0.1 × 10$^6$      | 7.7 ± 0.1               | 8.5 ± 0.9 × 10$^6$      | (0.19)                  | 904                     |
| PCI helix H mutant          |                         |                         |                         |                         |                         |                         |                          |                          |
| D298K/E301R/T302K/T309K     | 7.3 ± 0.1 × 10$^3$      | 3.6 ± 0.3               | 2.6 ± 0.2 × 10$^4$      | (1.6)                   | 8.4 ± 1.2 × 10$^6$      | 2.2 ± 0.1               | 1.8 ± 0.3 × 10$^7$      | (0.41)                  | 692                     |

Apparent second-order association rate constants ($k_{a,app}$) and SI (moles ZPI/mole FXa) for ZPI–FXa reactions were measured in the absence of PZ or in the presence of equimolar PZ plus 25 μM phospholipid, 5 mM CaCl$_2$ in 20 mM Tris, 0.1 M NaCl buffer (pH 7.4) at 25 °C as described under the “Experimental procedures” section. Buffer contained 2.5 mM CaCl$_2$ for reactions in the absence of PZ. The product of $k_{a,app}$ and SI represents the corrected association rate constant for reaction through the inhibitory pathway with values in parentheses expressing these rate constants relative to WT.

$^a$ Ratio of PZ-accelerated to unaccelerated values of $k_{a,app} \times$ SI.
To verify these differential heparin affinities for the two heparin-binding sites, we investigated the binding of heparin to ZPI mutants in which either the helix C site or the helix H site was mutated using tryptophan fluorescence quenching to monitor binding (Fig. 8, A and B). Significantly, the helix C site mutant ZPI (K104A/R105A/K113A/K116A) exhibited a marked reduction of tryptophan fluorescence quenching without evidence of saturation compared with WT in titrations of the mutant ZPI with both H5 and H72. The observed fluorescence quenching induced in the helix C mutant ZPI by both heparins was well fit by the binding equation assuming a WT quenching end point, which suggested a 10-fold to 20-fold weaker affinity of either heparin for the mutant ZPI compared with WT (KD of 1900 ± 200 μM for H5 binding and 10 ± 2 μM for H72 binding to the helix C site mutant ZPI versus 123 ± 23 μM for H5 binding and 1 ± 0.1 μM for H72 binding to WT). By contrast, titrations of the helix H site mutant (K260A/R263A/R305A/K308A/R310A) showed a significantly weaker affinity for both heparins compared with WT (KD of 300 ± 3 μM for H5 binding and 10 ± 2 μM for H72 binding to the helix H site mutant ZPI).

### Table 4

| ZPI mutant                  | k_{app} (M⁻¹ s⁻¹) | SI   | k_{app} × SI (M⁻¹ s⁻¹) | H50 rate enhancement |
|-----------------------------|-------------------|------|------------------------|----------------------|
| WT                          | 5.1 ± 0.4 × 10⁵   | 2.4 ± 0.1 | 1.2 ± 0.2 × 10⁶ (1)  | 75                   |
| D293A                       | 5.0 ± 0.2 × 10⁵   | 1.7 ± 0.1 | 8.5 ± 0.6 × 10⁶ (0.71) | 77                   |
| Helix H site mutations      |                   |      |                        |                      |
| K253A                       | 3.2 ± 0.2 × 10⁵   | 1.5 ± 0.1 | 4.8 ± 0.7 × 10⁵ (0.40) | 56                   |
| K260A                       | 1.6 ± 0.2 × 10⁵   | 1.7 ± 0.2 | 2.7 ± 0.6 × 10⁵ (0.22) | 27                   |
| R263A                       | 1.3 ± 0.1 × 10⁵   | 2.8 ± 0.1 | 3.5 ± 0.4 × 10⁵ (0.29) | 55                   |
| K284A                       | 3.9 ± 0.2 × 10⁵   | 2.4 ± 0.1 | 9.2 ± 0.9 × 10⁵ (0.77) | 77                   |
| R305A                       | 2.9 ± 0.3 × 10⁵   | 1.8 ± 0.1 | 5.3 ± 0.9 × 10⁵ (0.44) | 29                   |
| K308A                       | 2.4 ± 0.1 × 10⁵   | 2.2 ± 0.3 | 5.4 ± 0.9 × 10⁵ (0.45) | 32                   |
| R310A                       | 1.8 ± 0.1 × 10⁵   | 1.9 ± 0.2 | 3.5 ± 0.5 × 10⁵ (0.29) | 35                   |
| R260A/R263A                 | 1.2 ± 0.1 × 10⁵   | 2.5 ± 0.4 | 2.9 ± 0.8 × 10⁵ (0.24) | 22                   |
| K284A/R310A                 | 2.0 ± 0.1 × 10⁵   | 1.9 ± 0.1 | 3.7 ± 0.4 × 10⁵ (0.31) | 59                   |
| K260A/R263A/K308A/R310A     | 1.8 ± 0.1 × 10⁴   | 4.1 ± 0.6 | 7.6 ± 1.3 × 10⁴ (0.06) | 17                   |
| K260A/R263A/K308A/R310A     | 1.7 ± 0.1 × 10⁴   | 2.9 ± 0.4 | 4.9 ± 0.7 × 10⁴ (0.04) | 6.5                  |
| K253A/K260A/R263A/K308A/R310A | 6.4 ± 0.5 × 10⁻⁵ | 4.0 ± 0.2 | 2.6 ± 0.3 × 10⁴ (0.02) | 9.0                  |
| Helix C site mutations      |                   |      |                        |                      |
| K125A/R128A                 | 1.2 ± 0.1 × 10⁵   | 4.9 ± 0.2 | 5.6 ± 0.8 × 10⁵ (0.47) | 89                   |
| K104A/R105A/K113A/K116A     | 6.2 ± 0.1 × 10⁴   | 1.9 ± 0.2 | 1.2 ± 0.1 × 10⁵ (0.10) | 8.6                  |
| K104A/R105A/K113A/K125A/R128A | 8.5 ± 1.3 × 10⁻⁵ | 7.8 ± 2.0 | 6.6 ± 2.7 × 10⁴ (0.06) | 7.0                  |
| PCI helix H mutant          |                   |      |                        |                      |
| D298K/E301R/T302K/T309K     | 8.3 ± 0.4 × 10⁻⁵  | 4.6 ± 0.1 | 3.9 ± 0.2 × 10⁶ (3.2)  | 150                  |

Apparent second-order association rate constants (k_{app}) and SI (mole ZPI/mole FXa) for H50-accelerated reactions of ZPI with FXa were measured at the optimal heparin concentration of 1 μM in 20 mM Tris, 0.1 M NaCl, 2.5 mM CaCl₂ buffer (pH 7.4) at 25°C as described under the “Experimental procedures” section. The product of k_{app} and SI represents the corrected association rate constant for reaction through the inhibitory pathway with values in parentheses expressing these rate constants relative to WT.

a Ratio of heparin-accelerated to unaccelerated values of k_{app} × SI (the latter from Table 3).

---

**Figure 6.** Dependence of 50-saccharide heparin (H50) accelerating effects on ZPI inactivation of FXa on H50 concentration. The pseudo-first-order rate constant (k_{obs}) for reaction of 70 nM WT or mutant ZPIs with 0.5 nM FXa is plotted as a function of H50 concentration. Reactions were performed in 20 mM Tris buffer (pH 7.4), 0.1 M NaCl, 0.1 mg/ml BSA, 0.1% PEG 8000, and 2.5 mM CaCl₂ at 25°C. k_{obs} was calculated from the fractional loss of FXa activity at different reaction times and the mean of triplicate measurements ± SD plotted as described in the “Experimental procedures” section. Solid lines are computer fits of data by the template bridging model. BSA, bovine serum albumin; FXa, activated factor X; ZPI, protein Z-dependent protease inhibitor.
with the two heparins showed fluorescence quenching and heparin affinities similar to WT for both heparins \((K_D \text{ of } 142 \pm 42 \mu M \text{ for H5 binding and } 1.8 \pm 0.2 \mu M \text{ for H72 binding to the helix H site mutant})\). These findings suggest that the ZPI affinity for heparin largely derives from binding to the helix C site and are consistent with the results from elution of the mutants from heparin-Sepharose.

**Discussion**

While ZPI was initially characterized as a serpin whose anticoagulant function was dependent on PZ (ZPI naturally circulates as a tight complex with PZ in plasma \((8)\)), it was later shown that heparin was an additional major physiologic activator of ZPI anticoagulant function \((10)\). In this regard, ZPI resembles the anticoagulant serpins, AT, HCII, PN-1, and PCI, which all require heparin to inhibit their target coagulation proteases at physiologically significant rates. Like these serpins, heparin accelerates ZPI–protease reactions through a template bridging mechanism wherein heparin binding to both ZPI and the protease promotes the ternary complex encounter of the serpin with protease. Unlike these serpins, however, the heparin-binding site of ZPI was mapped to the helix C/D region of ZPI \((11)\), a site distinct from the site utilized by other anticoagulant serpins. Thus, AT, HCII, and PN-1 bind heparin through a conserved site in helix D, whereas PCI binds heparin in the helix H region \((1)\). Notably, the helix C/D site of ZPI is far removed from the PZ-binding site, which is centered on helix G, an observation that previously suggested that both heparin and PZ might bind ZPI simultaneously and form a ternary ZPI–PZ–heparin complex \((11)\). It was therefore surprising to recently find that when we subjected the ZPI–PZ complex to size-exclusion chromatography in the absence and presence of heparin, we found that heparin induced the dissociation of the complex, suggesting that heparin binding to ZPI antagonized PZ binding \((14)\).

In the present study, we have followed up this finding to convincingly demonstrate that heparin is indeed an antagonist of PZ binding to ZPI. While ZPI but not PZ alone was found to bind avidly to heparin-Sepharose, PZ was unable to bind to the resin even when complexed with ZPI. This suggested that binding of the ZPI–PZ complex to heparin-Sepharose through ZPI induces PZ to dissociate from the complex. Studies with an NBD-labeled ZPI, which report PZ binding by undergoing a complete quenching of the enhanced fluorescence of the ZPI–PZ complex when the complex was titrated with heparin, consistent with heparin displacing PZ from the complex. Heparin likewise was shown to reduce the affinity of PZ for ZPI as measured by direct titrations of NBD-ZPI with PZ in the absence and presence of heparin. Significantly, heparins as...
**Editors’ Pick: Heparin activation of ZPI blocks protein Z activation**

Figure 8. Heparin binds stronger to helix C site than to helix H site. Heparin-binding titrations of 200 nM WT (●), 1 µM helix C site mutant (K104A/R105A/K113A/K116A, ○), or 200 nM helix H site mutant (K260A/R263A/K305A/K308A/R310A, □) ZPIs monitored by protein fluorescence quenching at 340 nm (excitation, 280 nm) are shown for H5 binding (A) or for H72 binding (B). The data represent the average of three to five independent measurements, presented as mean ± SD. Some SD lines lie within the symbol. Solid lines are computer fits of the data by the quadratic binding equation with the quenching end point for the helix C mutant fixed at the WT end point. Other details are provided in the “Experimental procedures” section. ZPI, protein Z-dependent protease inhibitor.

small as five saccharides were effective at displacing PZ from the ZPI–PZ complex with the efficacy of heparins improving progressively with heparins of increasing chain length because of an increasing affinity of longer heparins for ZPI.

To understand how heparin antagonizes PZ binding, we considered the possibility that the previous mapping of the heparin-binding site had missed a heparin-binding region close to the PZ-binding site whose occupation by heparin directly interfered with PZ binding. Such an explanation was plausible given that mutation of the previous site did not completely abolish heparin binding and activation of ZPI (11). We thus employed the computer docking program, CLUSTER, with demonstrated success in mapping the heparin-binding sites of numerous proteins known to bind heparin (16, 19) to search for an additional heparin-binding site. The docking revealed not only the previously mapped helix C region but also a new favored site near helix H close to the heparin-binding site of the related A clade serpin, PCI.

Mutagenesis of basic residues in the predicted new helix H site confirmed the importance of these residues in heparin acceleration of ZPI inhibition of FXa. The related A clade serpin, PCI, uses a somewhat shifted site in helix H to bind heparin and accelerate PCI reactions with its target proteases. Grafting the PCI helix H basic residues, which bind heparin onto the homologous residues in ZPI, was found to enhance the heparin-accelerating effect on the mutant ZPI–FXa reaction, consistent with the helix H region of ZPI being a functional heparin-binding site.

Since the previous mapping of the helix C/D site had mostly used a chimeric approach and replaced larger secondary structures of the C and D helices with the corresponding regions of the nonheparin-binding serpin α₁-protease inhibitor, we reexamined the importance of the basic residues in this site. We confirmed the importance of the helix C and intervening loop residues but not the helix D residues for heparin acceleration of ZPI–protease reactions, consistent with the predictions of the docking program. Both sites thus seem important for heparin acceleration. Notably, the basic residues in the two sites form positive patches, which lie on the same face of ZPI (Fig. 7B), suggesting that both sites are involved in binding the long-chain heparins (>18 saccharides), which are required to accelerate ZPI–protease reactions (10). Unfortunately, we were unable to confirm whether complete abrogation of heparin acceleration could be achieved by mutating both sites since such a mutant was not expressable, possibly because of the cumulative effects of the destabilizing mutations K308A, R310A, and R128A (as analyzed by Site Directed Mutator, a server for predicting effects of mutations on protein stability (20)). It is also possible that other basic residues predicted to bind heparin in the helix C site whose contribution to heparin binding has not been tested (Fig. 4) may account for the inability to completely abrogate heparin acceleration.

Interestingly, heparin appeared to bind stronger to the helix C site than the helix H site based on the relative elution from heparin-Sepharose of ZPI variants with mutations in each site. This differential heparin affinity for the two sites was confirmed by intrinsic protein fluorescence quenching titrations of heparin binding to the helix C or helix H site mutants. Heparin affinity for ZPI thus derives largely from binding to the helix C site with a modest affinity augmentation in binding to the helix H site. Notably, the titrations revealed that the fluorescence quenching signaling heparin binding to ZPI could be induced by the binding of H5 or long-chain H72 either to the helix C site or to the helix H site. The binding of an H5 to ZPI through the higher affinity helix C site is thus sufficient to induce protein fluorescence quenching and to antagonize PZ binding (Fig. 2B) at the more distant PZ-binding site. This would imply that the protein fluorescence quenching and altered PZ binding accompanying heparin binding to ZPI results from allosterically induced global conformational changes in ZPI rather than proximity effects of heparin binding close to the PZ-binding site.

Intriguingly, only the helix H site is conserved in vertebrate ZPIs suggesting that for other vertebrate serpins, only the low-affinity helix H site exists, and thus, heparin may play a decreased role in activating ZPI in these species. This is
supporting our finding that the docking program for locating the heparin-binding site in mouse ZPI suggested only the helix H site. The two-site model for binding long-chain heparins thus appears to be unique to human ZPI. We would also note that the prediction of both helix H and helix C heparin-binding sites of human ZPI utilized the ZPI chains from two ZPI–PZ complex structures since the structure of uncomplexed human ZPI has not been reported. PZ has been shown to induce limited conformational changes in ZPI, which appear to play a minimal role in promoting ZPI–PZ complex inhibition of FXa on a procoagulant membrane (13) but could function to antagonize heparin binding. Such reciprocal effects of PZ binding to ZPI on heparin binding could not be determined because of the inability to study heparin binding to ZPI in the presence of PZ using intrinsic protein fluorescence changes. An altered conformation of ZPI in the ZPI–PZ complex structure that reduces ZPI affinity for heparin could explain why the docking program predicted potential heparin-binding sites other than helix C and helix H, although such sites were less favored.

In summary, our study has shown that heparin acts as an allosteric activator of ZPI by binding to an extended site and inducing global conformational changes in the serpin, which both accelerate ZPI inhibition of FXa and antagonize the binding and activation of ZPI by PZ. Thus, only heparin or PZ cofactors can be functional at a given time and location under physiologically relevant conditions. ZPI circulates in plasma primarily as a complex with PZ with a small fraction free (8). This complex is poised to bind to an activated platelet or an endothelial cell membrane through the γ-carboxyglutamic acid domain of PZ at a site of vascular injury and thereby inhibit FXa generated on the membrane at the fastest rate. However, FXa, which escapes from procoagulant membrane sites, may also be inhibited by free ZPI when bound to vascular heparan sulfate or heparin glycosaminoglycans at the injury site at a physiologically significant rate. If the circulating ZPI–PZ complex binds to these localized glycosaminoglycans, it will release PZ and spare the cofactor for binding to circulating-free ZPI. Such a mechanism would retain PZ cofactor function to enable ZPI to most efficiently inhibit FXa on a procoagulant membrane but would also permit heparin-bound ZPI to rapidly inhibit FXa released from the membrane and thereby ensure localization of blood clotting at the injury site and limit clotting in a time-dependent and space-dependent manner.

**Experimental procedures**

**Proteins**

Recombinant ZPI and mutants were expressed in *Escherichia coli* and purified to homogeneity as previously reported (12). DNA mutagenesis was carried out by PCR using the Quick-Change Mutagenesis kit (Stratagene). All mutations were confirmed by DNA sequencing. A single cysteine ZPI (K239C) with two native cysteines (C264 and C169) mutated to serine and alanine, respectively, was labeled with NBD fluorophore as previously described (15). Human plasma PZ and FXa were purchased from Enzyme Research Laboratories. All proteins were judged >95% pure by SDS-PAGE analysis. Molar concentrations of recombinant ZPI and plasma PZ were determined from the absorbance at 280 nm using absorption coefficients calculated from the amino acid sequence (15). FXa concentrations were determined by a standard assay with chromogenic substrate that was calibrated with protease of known active-site concentration (18).

**Phospholipids**

Small and unilamellar phospholipid vesicles were prepared from a 7:3 mixture (by weight) of dioleyl phosphatidylcholine and dioleoyl phosphatidylserine (Avanti Polar Lipids) as described previously (18).

**Heparin**

Heparins with a narrow molecular weight distribution and average chain length of 26 to 72 saccharides were purified from porcine mucosal heparin (Diosynth) by repeated gel exclusion chromatography and affinity fractionation for AT, as described previously (21). Oligosaccharide heparins from 4 to 18 saccharides in length were a generous gift of Ingemar Björk and prepared by chemical degradation of commercial heparin followed by chromatographic purification (22). An exception was a synthetic H5 (fondaparinux), which was a gift of Sanofi. Molar concentrations of heparins were determined from the weight concentration obtained by an Azure A dye–binding assay together with the molecular weight (21).

**ZPI–PZ binding to heparin-Sepharose analyzed by SDS-PAGE and immunoblotting**

Samples of 500 nM ZPI, ZPI–PZ complex, or PZ, in 20 μl of 50 mM Tris buffer (pH 7.4), 0.1 M NaCl, and 2.5 mM CaCl2 were mixed with 50 μl heparin-Sepharose resin equilibrated with the same buffer and then transferred to a small column with the outlet closed. After incubation for 40 min at room temperature, the outlet was opened and the unbound proteins were allowed to flow through the column. The flowthrough was collected, and the columns were then washed three times with 20 volumes of equilibrating buffer. The wash buffer was discarded, and the resins were resuspended in 200 μl of the same buffer. The flow-through and resuspended resin were mixed with SDS sample buffer containing 100 mM dithiothreitol, heated at 100 °C for 5 min, and then subjected to 10% SDS-PAGE. The proteins were transferred to a polyvinylidene difluoride membrane and analyzed by anti-ZPI (Sigma–Aldrich) and anti-PZ (Haematologic Technologies) antibodies.

**Fluorescence emission spectra and equilibrium binding of PZ or heparin to labeled and unlabeled ZPI**

Fluorescence emission spectra of NBD-ZPI (50–100 nM) were measured in the absence or the presence of PZ and heparin in 20 mM Tris buffer (pH 7.4), 0.2 M NaCl, 0.1% PEG 8000, 1 mg/ml bovine serum albumin (BSA), and 2.5 mM CaCl2 with an SLM 8000 spectrofluorometer with excitation at 480 nm over the emission range of 500 to 600 nm. Intrinsic protein fluorescence of WT and mutant ZPIs (200 nM to 1 μM) was measured in the same buffer without BSA, with excitation at 280 nM over the emission range of 300 to...
400 nm. Emission was monitored in 5-nm steps with 5 to 10 s of integrations per step. Spectra were obtained in triplicate and averaged. Buffer, buffer plus PZ, or buffer plus heparin background spectra were subtracted, and dilution corrections were made for added PZ or heparin (<10%).

Equilibrium binding of heparin to NBD-ZPI was measured by competitive binding titrations in which heparins of various lengths were titrated into NBD-ZPI (50 nM) complexed with a molar excess of PZ (62 nM) in a lower ionic strength buffer (0.1 M NaCl) and heparin binding followed by the quenching of NBD-ZPI–PZ complex fluorescence. Titrations were monitored from the enhancement of NBD-ZPI fluorescence accompanying heparin binding at excitation and emission wavelengths of 280 and 340 nm, respectively. Titrations were computer fit by the aforementioned quadratic binding equation, with [H]o replacing [PZ]o and KD,H replacing KD,PZapp.

**ZPI–heparin docking analysis**

The program CLUSPRO was used to virtually dock a heparin tetrasaccharide to the ZPI chain of the two available ZPI–PZ complex structures (PDB code: 3F1S and 3H5C) and to uncomplexed mouse ZPI (PDB code: 4AJT). The program evaluates a billion docking poses of a generic heparin tetrasaccharide with ZPI and clusters the 1800 lowest energy docking positions based on ligand positions lying within a 9 Å RMSD radius in each cluster (16).

**Kinetics of ZPI–FXa reactions**

Heparin accelerating effects on the kinetics of ZPI–FXa reactions were evaluated as a function of heparin concentration under pseudo–first-order conditions (i.e., with a large molar excess of inhibitor over protease) by incubating reaction mixtures of 100 μl containing 70 nM ZPI and ~0.5 nM FXa in the absence or presence of varying levels of H50 ranging from 10−9 to 10−4 M in 20 mM Tris buffer (pH 7.4), 0.1 M NaCl, 0.1% PEG 8000, 0.1 mg/ml BSA, and 2.5 mM CaCl2 at 25°C for reaction times of 2 to 5 min. Reactions were quenched by adding 1 ml of 50 μM Pefabloc FXa substrate (Centerchem, Inc) containing 50 μg/ml polybrene and 5 mM EDTA. The initial linear rate of substrate hydrolysis was monitored at an excitation wavelength of 380 nm and an emission wavelength of 440 nm. The observed pseudo–first-order rate constant for reactions (kobs) was calculated from the equation,

\[
k_{ob} = \ln([v_i - v_\infty]/[v_i - v_\infty])/t
\]

where vi and v∞ are the initial velocities of protease hydrolysis of the substrate after reaction with ZPI for the fixed reaction time and after reaching the reaction end point, respectively, and t is the fixed reaction time. The dependence of kobs on

\[
\Delta F_{\text{obs}} = \Delta F_{\text{max}} \times \frac{[\text{ZPI}]_0 + [\text{PZ}]_0 + KD,PZapp}{2 \times [\text{ZPI}]_0} - \sqrt{([\text{ZPI}]_0 + [\text{PZ}]_0 + KD,PZapp)^2 - 4 \times [\text{ZPI}]_0 \times [\text{PZ}]_0}
\]

where ΔFobs/F₀ and ΔFmax/F₀ are the observed and maximal fluorescence changes after addition of PZ expressed relative to the initial free NBD-ZPI fluorescence, respectively, and KD,PZapp = KD,PZ × (1 + [H]o/KD,H) is the apparent dissociation constant for the ZPI–PZ interaction in the absence or presence of heparin.

The fitted parameters were KD,PZapp and ∆Fmax/F₀.

Direct equilibrium binding of heparin to ZPI was measured by titrations of unlabeled WT and variant ZPIs (0.2–1 μM) with heparin monitored by the quenching of intrinsic protein fluorescence accompanying heparin binding at excitation and emission wavelengths of 280 and 340 nm, respectively. Titrations were computer fit by the aforementioned quadratic binding equation
heparin concentration was computer fit by nonlinear least squares analysis by the ternary complex bridging model equation (10).

Apparent second-order rate constants for unacelerated and H50-accelerated ZPI–FXa reactions were measured in the absence and presence of the optimal H50 concentration under pseudo-first-order conditions by analyzing full ZPI–FXa reaction progress curves over the ZPI concentration range of 10 to 900 nM with ~0.5 nM FXa. Full reaction progress curves were also measured for ZPI–FXa reactions in the presence of PZ equimolar with ZPI, 25 μM lipid, and 5 mM CaCl2, as a function of the ZPI concentration in the range of 10 to 40 nM. Identical reaction mixtures were quenched at varying reaction times with substrate, and the time course of protease inactivation was measured from the decrease in initial rates of substrate hydrolysis. The first-order rate of decrease in protease activity with time was computer fit by a single exponential decay function with a nonzero end point and $k_{\text{obs}}$ obtained from the fitted exponential decay constant. Apparent second-order association rate constants ($k_{a,\text{app}}$) were obtained from the slopes of linear plots of $k_{\text{obs}}$ versus the ZPI concentration according to the equation,

$$k_{\text{obs}} = k_d + k_{a,\text{app}} \times [\text{ZPI}]_0$$

In which $k_d$ represents the rate constant for ZPI–FXa complex dissociation and $[\text{ZPI}]_0$ is the total ZPI concentration. $k_d$ was fixed at the experimentally determined value of $10^{-4}$ s⁻¹ for WT and ZPI mutants as described (18).

**Stoichiometries of ZPI reaction with FXa**

Fixed concentrations of FXa (50–100 nM FXa) were reacted with increasing concentrations of ZPI, ranging from a approximately threefold to sevenfold molar excess, in the absence of cofactors or in the presence of either 1 μM H50 or PZ equimolar with ZPI, 25 μM lipid, and 5 mM CaCl2, in kinetics buffer at 25 °C in reaction volumes of 50 μl. After allowing sufficient time to reach a reaction end point, based on measured second-order associate rate constants (~5–30 min), remaining proteolytic activity was measured by reacting an aliquot (5–20 μl) of the reaction mixtures with 1 ml of 100 μM Spectrozyme FXa (American Diagnostica) containing 50 μg/ml Polybrene and 5 mM EDTA and monitoring the rate of absorbance change at 405 nm. The apparent SI was determined from the fitted abscissa intercept of a linear plot of residual protease activity against the molar ratio of inhibitor to protease (18). Because the ZPI–PZ complex dissociates to a small extent over the reaction time, apparent SIs depend on the time of incubation. To correct for such complex dissociation, apparent SIs were multiplied by the factor, $\exp \left( -k_d t \right)$, where $k_d$ is the measured complex dissociation rate constant of $10^{-4}$ s⁻¹ and $t$ the fixed reaction time. Simulations verified the validity of this correction for small extents of dissociation. Reported SIs are average values of at least two independent measurements at different reaction times.

**Relative affinities of ZPI variants for heparin-Sepharose**

WT and mutant ZPIs (~25 μg) in 1 ml equilibrating buffer of 20 mM Tris (pH 7.4), 0.2 M NaCl, and 2.5 mM CaCl2 were applied to a 1 ml HiTrap heparin column and eluted with a salt gradient from 0.2 to 0.55 M NaCl with continuous monitoring of the eluant by protein fluorescence. Salt concentrations corresponding to the peak elution position of the protein were calculated from the elution volume based on calibration of the volumes at the beginning and end of the gradient (10).

**Data availability**

All data are contained within the article.

**Acknowledgments**—We thank Dr Peter Gettins of the Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, for critical comments on the article. We thank Aiwu Zhou, Shanghai JiaoTong University, for kindly providing the ZPI expression plasmid.

**Author contributions**—X. H. conceptualization; X. H. and S. T. O validation; X. H., R. S., and S. T. O. investigation; X. H. and S. T. O. data curation; X. H. and S. T. O. writing—original draft; X. H., R. S., and S. T. O. writing—review and editing; X. H. supervision.

**Funding and additional information**—This research was supported by a grant from the National Institutes of Health, United States (grant no: R56 HL149881; to X. H.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: AT, antithrombin; BSA, bovine serum albumin; FXa, activated factor X; HCII, heparin cofactor II; H5, pentasaccharide heparin; H50, 50-saccharide heparin; H72, 72-saccharide heparin; NBD, N,N'-dimethyl-N-(acetyl)-N'-(7-nitrobenz-3-oxa-1,3-diazol-4-yl) ethylenediamine; PCI, protein C inhibitor; PDB, Protein Data Bank; PN-1, protease nexin 1; PZ, protein Z; SI, stoichiometry of inhibition; ZPI, protein Z-dependent protease inhibitor.

**References**

1. Gettins, P. G. (2002) Serpin structure, mechanism, and function. *Chem. Rev.* 102, 4751–4804
2. Olson, S. T., Bjork, L., and Bock, S. C. (2002) Identification of critical molecular interactions mediating heparin activation of antithrombin: implications for the design of improved heparin anticoagulants. *Trends Cardiovasc. Med.* 12, 198–205
3. Tollefsen, D. M. (1997) Heparin cofactor II. *Adv. Exp. Med. Biol.* 425, 35–44
4. Stone, S. R., Brown-Luedi, M. L., Rovelli, G., Guidolin, A., McGlynn, E., and Monard, D. (1994) Localization of the heparin-binding site of gliaderived nexin/protease nexin-1 by site-directed mutagenesis. *Biochem. Biophys. Res. Commun.* 33, 7731–7735
5. Neece, L. L., Wolfe, C. A., and Church, F. C. (1998) Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor. *Arch. Biochem. Biophys.* 355, 101–108
6. Shirk, R. A., Elisen, M. G., Meijers, J. C., and Church, F. C. (1994) Role of the H helix in heparin binding to protein C inhibitor. J. Biol. Chem. 269, 28690–28695
7. Han, X., Huang, Z. F., Fiehler, R., and Broze, G. J., Jr. (1999) The protein Z-dependent protease inhibitor is a serpin. Biochemistry 38, 11073–11078
8. Tabatabai, A., Fiehler, R., and Broze, G. J., Jr. (2001) Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb. Haemost. 85, 655–660
9. Han, X., Fiehler, R., and Broze, G. J., Jr. (2000) Characterization of the protein Z-dependent protease inhibitor. Biochemistry 38, 11073–11078
10. Huang, X., Rezaie, A. R., Broze, G. J., Jr., and Olson, S. T. (2001) Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor. J. Biol. Chem. 269, 28690–28695
11. Tabatabai, A., Fiehler, R., and Broze, G. J., Jr. (2001) Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb. Haemost. 85, 655–660
12. Wei, Z., Yan, Y., Carrell, R. W., and Zhou, A. (2009) Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X. Blood 114, 3662–3667
13. Huang, X., Dementiev, A., Olson, S. T., and Gettins, P. G. (2010) Basis for the specificity and activation of the serpin protein Z-dependent protease inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa. J. Biol. Chem. 285, 20399–20409
14. Huang, X., Liu, B., Wei, Y., Beyea, R., Yan, H., and Olson, S. T. (2017) Lipid oxidation inactivates the anticoagulant function of protein Z-dependent protease inhibitor (ZPI). J. Biol. Chem. 292, 14625–14635
15. Huang, X., Zhou, J., Zhou, A., and Olson, S. T. (2015) Thermodynamic and kinetic characterization of the protein Z-dependent protease inhibitor (ZPI)-protein Z interaction reveals an unexpected role for ZPI Lys-239. J. Biol. Chem. 290, 9906–9918
16. Mottarella, S. E., Beglov, D., Beglova, N., Nugent, M. A., Kozakov, D., and Vajda, S. (2014) Docking server for the identification of heparin binding sites on proteins. J. Chem. Inf. Model. 54, 2068–2078
17. Huang, X., Yan, Y., Tu, Y., Gatti, J., Broze, G. J., Jr., Zhou, A., et al. (2012) Structural basis for catalytic activation of protein Z-dependent protease inhibitor (ZPI) by protein Z. Blood 120, 1726–1733
18. Huang, X., Swanson, R., Broze, G. J., Jr., and Olson, S. T. (2008) Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa. J. Biol. Chem. 283, 29770–29783
19. Kozakov, D., Hall, D. R., Xia, B., Porter, K. A., Padhorny, D., Yueh, C., et al. (2017) The ClusPro web server for protein-protein docking. Nat. Protoc. 12, 255–278
20. Pandurangan, A. P., Ochoa-Montano, B., Ascher, D. B., and Blundell, T. L. (2017) SDM: a server for predicting effects of mutations on protein stability. Nucl. Acids Res. 45, W229–W235
21. Olson, S. T., Bjork, I., and Shore, J. D. (1993) Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteases by antithrombin. Methods Enzymol. 222, 525–559
22. Olson, S. T., Halvorson, H. R., and Bjork, I. (1991) Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J. Biol. Chem. 266, 6342–6352
23. Lindahl, P., Raub-Segall, E., Olson, S. T., and Bjork, I. (1991) Papain labelled with fluorescent thiol-specific reagents as a probe for characterization of interactions between cysteine proteinases and their protein inhibitors by competitive titrations. Biochem. J. 276, 387–394

Dr Xin Huang is a research faculty in the Department of Pharmacology and Regenerative Medicine at the University of Illinois Chicago (UIC). He studies the molecule mechanism of blood coagulation. In particular, he is interested in how serpin family member proteins regulate the coagulation process. He is also interested in developing new treatments for bleeding and thrombosis diseases.